US2004116381A1PendingUtilityA1

Method of predicting the structural integrity of mamalian tissue

57
Priority: Dec 16, 2002Filed: Mar 7, 2003Published: Jun 17, 2004
Est. expiryDec 16, 2022(expired)· nominal 20-yr term from priority
Inventors:Bruce Daniels
A61K 31/727A61K 31/715
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention claimed is a method of predicting the structural integrity of a mammalian tissue comprising the steps of measuring an amount of a heparanoid-like substance in a mammalian bodily excretion then referring to a predictive chart showing a correlation between the amount of the heparanoid-like substance in the mammalian bodily excretion in relation to an amount of the heparanoid-like substance in said mammalian tissue and then predicting the amount of heparanoid-like substance in said mammalian tissue from the amount of heparanoid-like substance measured in the mammalian bodily excretion.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method of predicting the structural integrity of a mammalian tissue comprising the steps of: 
 (a) measuring an amount of a heparanoid-like substance in a mammalian bodily excretion;    (b) referring to a predictive chart showing a correlation between the amount of the heparanoid-like substance in the mammalian bodily excretion in relation to an amount of the heparanoid-like substance in said mammalian tissue;    (c) predicting the amount of heparanoid-like substance in said mammalian tissue from the amount of heparanoid-like substance measured in the mammalian bodily excretion.    
     
     
         2 . The method of  claim 1  wherein the heparanoid-like substance is Rhamnan Sulphate.  
     
     
         3 . The method of  claim 1  wherein the bodily excretion is feces.  
     
     
         4 . The method of  claim 1  wherein the bodily excretion is urine.  
     
     
         5 . The method of  claim 1  wherein the chart is an equation.  
     
     
         6 . The method of  claim 1  wherein the mammal is human.  
     
     
         7 . The method of  claim 1  wherein the tissue is the endothelium.  
     
     
         8 . The method of  claim 1  wherein the tissue is the cellular matrix.  
     
     
         9 . The method of  claim 1  wherein the amount of heparanoid-like substance is measured in a volume of liquid to give a concentration of heparanoid-like substance.  
     
     
         10 . The method of  claim 9  wherein the predictive chart shows the correlation between the concentration of bodily excretion heparanoid-like substance in relation to a concentration of heparanoid-like substance in mammalian tissue.  
     
     
         11 . The method of  claim 10  wherein the mammalian tissue is the endothelium.  
     
     
         12 . The method of  claim 1  wherein a mammalian tissue heparanoid-like substance amount between an optimal range is indicative of desirable tissue structural integrity.  
     
     
         13 . The method of  claim 1  wherein a tissue heparanoid-like substance concentration outside of an optimal range is indicative of undesirable tissue structural integrity.  
     
     
         14 . The method of  claim 1  wherein the mammalian tissue structural integrity is used to predict the overall health state of the mammal.  
     
     
         15 . The method of  claim 14  wherein a desirable mammalian tissue structural integrity indicates desirable healthy state.  
     
     
         16 . The method of  claim 15  wherein a desirable healthy state indicates a reduced risk of thrombogenecity.  
     
     
         17 . The method of  claim 15  wherein the desirable healthy state indicates a reduced risk of heart attack.  
     
     
         18 . The method of  claim 15  wherein a desirable healthy state indicates a reduced risk of ischemia.  
     
     
         19 . The method of  claim 15  wherein a desirable healthy state indicates a reduced risk of arterial stenosis.  
     
     
         20 . The method of  claim 15  wherein a desirable healthy state indicates a reduced risk of cardiac cell hypertrophy.  
     
     
         21 . The method of  claim 15  wherein a desirable healthy state indicates a reduced risk of myocardial infarction.  
     
     
         22 . The method of  claim 15  wherein a desirable healthy state indicates a reduced risk of angina pectoris.  
     
     
         23 . The method of  claim 15  wherein a desirable healthy state indicates a reduced risk of hypertension.  
     
     
         24 . The method of  claim 15  wherein a desirable healthy state indicates a reduced risk of endothelial dysfunction.  
     
     
         25 . The method of  claim 15  wherein a desirable healthy state indicates a reduced risk of cardiovascular disease.  
     
     
         26 . The method of  claim 25  wherein the cardiovascular disease is atherosclerosis.  
     
     
         27 . The method of  claim 25  wherein the cardiovascular disease is arteriosclerosis.  
     
     
         28 . The method of  claim 25  wherein the cardiovascular disease is thrombosis.  
     
     
         29 . The method of  claim 14  wherein an undesirable mammalian tissue structural integrity indicates an undesirable healthy state.  
     
     
         30 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of thrombogenecity.  
     
     
         31 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of congestive heart failure.  
     
     
         32 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of arterial stenosis.  
     
     
         33 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of myocardial infarction.  
     
     
         34 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of cardiac cell hypertrophy.  
     
     
         35 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of angina pectoris.  
     
     
         36 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of hypertension.  
     
     
         37 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of endothelial dysfunction.  
     
     
         38 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk for heart attack.  
     
     
         39 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of ischemia.  
     
     
         40 . The method of  claim 22  wherein an undesirable healthy state indicates an increased risk of cardiovascular disease.  
     
     
         41 . The method of  claim 40  wherein the cardiovascular disease is atherosclerosis.  
     
     
         42 . The method of  claim 40  wherein the cardiovascular disease is arteriosclerosis.  
     
     
         43 . The method of  claim 40  wherein the cardiovascular disease is thrombosis.

Join the waitlist — get patent alerts

Track US2004116381A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.